Sep 2026· Advancement of science· 0 citations· 46 references
Medicine
TL;DR
This work identifies RNA‐binding motif protein 25 (RBM25) as a potent oncogenic driver that is overexpressed in HCC and correlates with dismal patient prognosis and nominate RBM25 as a viable prognostic biomarker and therapeutic target.
Abstract
ABSTRACT Deregulated alternative splicing (AS) is a hallmark of hepatocellular carcinoma (HCC), yet the specific splicing factors driving oncogenic programs remain largely uncharacterized. Here, we identify RNA‐binding motif protein 25 (RBM25) as a potent oncogenic driver that is overexpressed in HCC and correlates with dismal patient prognosis. Functionally, RBM25 depletion impairs HCC progression across in vitro models, in vivo xenografts, and patient‐derived organoids. Integrated transcriptomic and interactome profiling reveals that RBM25 orchestrates a specific AS landscape, most notably promoting exon 13 inclusion of MYPT1. Mechanistically, RBM25 recruits PRPF40A to facilitate the production of the oncogenic MYPT1‐L isoform. This isoform switch acts as a molecular stabilizer for the transcriptional co‐activator YAP, thereby sustaining Hippo pathway dysregulation and tumor growth. Finally, a high‐throughput screen of the US drug collection identified candicidin as a small‐molecule inhibitor that suppresses RBM25 expression, effectively phenocopying RBM25 knockdown. Our findings define the RBM25‐MYPT1‐YAP axis as a critical vulnerability in HCC and nominate RBM25 as a viable prognostic biomarker and therapeutic target.
ABSTRACT Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, yet mechanisms sustaining malignant progression remain incompletely defined. Integrative analyses across multiple HCC cohorts identified TUBA1B as one of the most consistently upregulated tubulin isotypes whose high expression associates wi...
Feng Lin, Hechun Lin, Junming Yu et al.· Advancement of science· 0 citations
The long noncoding RNA H19 has been widely attested as a promoter of breast cancer by favoring proliferation, migration, invasion, and tumor growth. In this study, we attempted to decipher molecular mechanisms underlying oncogenic activities of H19. Transcriptomic analyses revealed that H19 overexpression correlates wi...
Kekely Klouyovo, Evodie Peperstraete, Léa Mabille et al.· The FEBS Journal· 0 citations
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and the upstream regulatory mechanisms driving oncogenic signaling remain insufficiently defined. In this study, we identify a previously unrecognized nuclear function of the cytoskeletal protein ACTB in promoting ESCC prog...
Yun-Shan Jiang, Dan Zhao, D. Liao et al.· Oncogene· 0 citations
Integrated transcriptomic and translatomic profiling demonstrated that this axis orchestrated extensive reprogramming of mRNA metabolism, ribosome biogenesis and cancer-associated signaling pathways, underscoring its multilayered role in tumor progression.
Sha Yang, Zhen Shang, Shun-Xiang Xia et al.· International Journal of Onc...· 0 citations
It is demonstrated that the TUBB4B inhibitor, mebendazole, effectively suppresses the enhanced proliferation in lower‐expression PNLDC1 models, positioning it as a promising therapeutic agent.
Pulmonary metastasis is the leading cause of mortality in osteosarcoma patients, yet the molecular mechanisms that sustain invasive malignancy within metastatic niches remain poorly understood. Through analysis of single-cell transcriptomic data from osteosarcoma lung metastases and clinical survival datasets, this s...
Jia-Min Zhang, Jia-Hui Guo, Xun-Rui Chen et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.